InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook
InMode Ltd. (Nasdaq: INMD) announced its third-quarter 2026 financial results, reporting GAAP revenues of $92.1 million, which was largely consistent with the $93.2 million reported in the same period last year. While capital equipment revenue remained stable across U.S. and international markets, revenues from consumables and services saw a slight decline of 3% year-over-year to $19.3 million. The company maintained a gross margin of 78%, aided by a non-recurring U.S. tariff refund. However, operating margins decreased due to restructuring costs in North America and increased investments in sales, marketing, and professional services. Despite these expenses, InMode maintains a strong liquidity position with $512.7 million in cash and marketable securities and has reaffirmed its full-year 2026 financial outlook.
Coverage
- InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook
- First International Bank of Israel Reports Q3 2026 Financial Results
- Edible Garden Schedules Q3 2026 Financial Results and Business Update Conference Call
- Archer Aviation Reports Q3 2026 Results with First Powertrain Revenue from Anduril
- Archer Aviation Inc. - 10-Q Filing
- KKR & Co. declares $0.195 dividend
- ContextLogic Reports Q3 2026 GAAP EPS of -$0.29 and Revenue of $32.2 Million
- GS BDC (GSBD) Reports Q3 2026 Financial Results with Decreased NAV and Rising Nonaccruals
- Allogene targets ALPHA3 enrollment completion by year-end 2027 while planning midyear 2027 clinical update
- Barings BDC Reports Q3 2026 Results with Slight NAV and NII Decline
- Lexicon Pharmaceuticals Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Leapfrog Acquisition Corp - 10-Q Filing
- PROCEPT BioRobotics Corp - 10-Q Filing
- Meridian3 Industrials Acquisition Corp - 10-Q Filing
- uniQure Reports Q3 2026 Financial Results and AMT-130 Clinical Updates
- Nuvectis Pharma Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Royalty Pharma plc - 10-Q Filing
- UroGen Pharma Ltd. - 8-K Filing
- Nuvectis Pharma, Inc. - 10-Q Filing
- uniQure N.V. - 8-K Filing
- uniQure N.V. - 4 Filing
- FDA Grants Priority Review for uniQure's Huntington's Disease Gene Therapy
- uniQure N.V. - 8-K Filing